The diagnosed and drug-treated FM population is expected to grow by 1.7 million persons by 2020, according to a recent news release by the market analyst firm Decision Resources Group. But, barring new & improved drug entries, the FM-specific prescription drug market will ‘only’ grow by $200 million (from $1.6 billion to $1.8 billion each year by 2020) as receipts for two branded drugs approved by the FDA for prescription to fibromyalgia patients – Cymbalta and Lyrica – start to be ‘eroded’ by sale of generic (non-branded and thus less expensive) versions of the drugs.
Taking up some of the slack from generic erosion of Cymbalta and Lyrica will be predicted increases in sales of the branded drugs Savella (aka milnacipran), Nycynta ER (tapentadol ER) and Lyrica (pregabalin). Helped of course by the basic growth in the diagnosed patient population.
Other facts in the report are that the US accounted for 80% of the $1.6 billion fibromyalgia drug market in 2010, and should account for about two-thirds of the $1.8 billion market in 2020. One wild card is that “ample opportunity” remains for new prescription therapies that could improve on the efficacy and tolerability of the current leading FDA-approved drugs.